Drugs / TGFBR-2 KO CD70 CAR NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07072234 | Sep 2025 → Feb 2028 expected | clear cell renal carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGFBR-2 KO CD70 CAR NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07072234 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor TGFBR-2 KO CD70 CAR NK cells” NCT07072234 ↗ |
| Route | Intravenous | “Given by IV” NCT07072234 ↗ |
| Target | CD70 | “TGFBR-2 KO CD70 CAR NK cells” NCT07072234 ↗ |